test

Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive (AURA2)

Conditions

Lung

What is the purpose of this trial?

To assess the efficacy of AZD9291 by assessment of Objective Response Rate (ORR).


Participation Guidelines

Age:
18 Years and older
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Astra Zeneca, L.P.
Dates:
07/28/2014
Last Updated:
Study HIC#:
1404013874